Pure Global
NCT06293300

Understanding and Treating Traumatic Brain Injury (TBI) Associated Photophobia With Botulinum Toxin Type A (BoNT-A)

Understanding and Treating TBI Associated Photophobia With Botulinum Toxin Type A and Its Impact on Visual Function
University of Miami·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Traumatic Brain Injury
Drug/Device/Intervention
BoNT A
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
University of Miami
Location
Miami, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Aug 01, 2024
End date
Aug 30, 2026
Enrollment
50 participants
Primary outcome

Change in photophobia measured by Numerical Rating Scale,Change in visual photosensitivity thresholds (VPT) measured Ocular Photosensitivity Analyzer (OPA)

Summary

The purpose of this research is to understand and treat Traumatic Brain Injury (TBI)
 associated photophobia (light sensitivity) and its impact on visual function.

ICD-10 classifications
Diffuse brain injuryIntracranial injuryFocal brain injuryIntracranial injury, unspecifiedOther intracranial injuries
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06293300
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06293300 through Pure Global AI's free database. This Phase 2 trial is sponsored by University of Miami and is currently Not yet recruiting. The study focuses on Traumatic Brain Injury. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.